42 research outputs found
RNA delivery by extracellular vesicles in mammalian cells and its applications.
The term 'extracellular vesicles' refers to a heterogeneous population of vesicular bodies of cellular origin that derive either from the endosomal compartment (exosomes) or as a result of shedding from the plasma membrane (microvesicles, oncosomes and apoptotic bodies). Extracellular vesicles carry a variety of cargo, including RNAs, proteins, lipids and DNA, which can be taken up by other cells, both in the direct vicinity of the source cell and at distant sites in the body via biofluids, and elicit a variety of phenotypic responses. Owing to their unique biology and roles in cell-cell communication, extracellular vesicles have attracted strong interest, which is further enhanced by their potential clinical utility. Because extracellular vesicles derive their cargo from the contents of the cells that produce them, they are attractive sources of biomarkers for a variety of diseases. Furthermore, studies demonstrating phenotypic effects of specific extracellular vesicle-associated cargo on target cells have stoked interest in extracellular vesicles as therapeutic vehicles. There is particularly strong evidence that the RNA cargo of extracellular vesicles can alter recipient cell gene expression and function. During the past decade, extracellular vesicles and their RNA cargo have become better defined, but many aspects of extracellular vesicle biology remain to be elucidated. These include selective cargo loading resulting in substantial differences between the composition of extracellular vesicles and source cells; heterogeneity in extracellular vesicle size and composition; and undefined mechanisms for the uptake of extracellular vesicles into recipient cells and the fates of their cargo. Further progress in unravelling the basic mechanisms of extracellular vesicle biogenesis, transport, and cargo delivery and function is needed for successful clinical implementation. This Review focuses on the current state of knowledge pertaining to packaging, transport and function of RNAs in extracellular vesicles and outlines the progress made thus far towards their clinical applications
Transcriptome reprogramming by cancer exosomes: identification of novel molecular targets in matrix and immune modulation
We thank the Facial Surgery Research Foundation â Saving Faces; Guizhou Department of Education and Guizhou Science and Technology Department
LPS-preconditioned mesenchymal stromal cells modify macrophage polarization for resolution of chronic inflammation via exosome-shuttled let-7b
The role of microRNA in myelodysplastic syndromes: beyond DNA methylation and histone modification
Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma
MicroRNAs (miRNAs) circulate in the bloodstream in a highly stable, extracellular form and are being developed as blood-based biomarkers for cancer and other diseases. However, the mechanism underlying their remarkable stability in the RNase-rich environment of blood is not well understood. The current model in the literature posits that circulating miRNAs are protected by encapsulation in membrane-bound vesicles such as exosomes, but this has not been systematically studied. We used differential centrifugation and size-exclusion chromatography as orthogonal approaches to characterize circulating miRNA complexes in human plasma and serum. We found, surprisingly, that the majority of circulating miRNAs cofractionated with protein complexes rather than with vesicles. miRNAs were also sensitive to protease treatment of plasma, indicating that protein complexes protect circulating miRNAs from plasma RNases. Further characterization revealed that Argonaute2 (Ago2), the key effector protein of miRNA-mediated silencing, was present in human plasma and eluted with plasma miRNAs in size-exclusion chromatography. Furthermore, immunoprecipitation of Ago2 from plasma readily recovered nonâvesicle-associated plasma miRNAs. The majority of miRNAs studied copurified with the Ago2 ribonucleoprotein complex, but a minority of specific miRNAs associated predominantly with vesicles. Our results reveal two populations of circulating miRNAs and suggest that circulating Ago2 complexes are a mechanism responsible for the stability of plasma miRNAs. Our study has important implications for the development of biomarker approaches based on capture and analysis of circulating miRNAs. In addition, identification of extracellular Ago2âmiRNA complexes in plasma raises the possibility that cells release a functional miRNA-induced silencing complex into the circulation
No evidence of somatotopic place of articulation feature mapping in motor cortex during passive speech perception
Microparticles and exosomes in cell-cell communication
Growing evidence indicates that cells are able to communicate with neighbouring and distant cells in the body by production of extracellular vesicles (EV). EV are classified according to their size and mechanisms of formation. Exosomes and microparticles are the most extensively studied clinically relevant forms of EV, and they often reflect the activation status of the parent cell, by carrying similar surface markers and cargo. Because of these molecular characteristics, EV are considered to be mediators of cell activation by transferring molecules (e.g., proteins, lipids, and nucleic acids) to neighbouring or distant cell populations. Increased levels of circulating EV have been observed in various diseases, including hypertension, atherosclerosis, kidney diseases, and cancer. In this chapter, we will address the formation of different EV and their importance in cell-cell communication, controlling basic cellular functions in homeostatic and pathologic conditions associated with cardiovascular diseases. In addition, we highlight their role as biomarkers and discuss the potential of EV as therapeutic tools